Skip to content

Teicoplanin

    Brands

    Teicoplanin

    DAE Class; Rx

    Common Brand Names; TARGOCID

    • Other inhibitors of cell wall synthesis

    Teicoplanin is a glycopeptide antibiotic. Teicoplanin is very similar to Vancomycin in mechanism of action and antibacterial spectrum. Teicoplanin is effective against gram positive bacteria. Antibiotics require constant drug level in body for therapeutic effect. This is achieved by taking the drug at regular intervals of time throughout the day and night as prescribed. Teicoplanin is important to take the drug for the full time period as prescribed. discontinuation of the drug, may result in ineffective treatment.

    Teicoplanin is primarily indicated in conditions like Bacillary dysentery, Bacterial infections, Constipation, Constipation and bowel evacuation, Endocarditis, Endocarditis treatment, GI infections, Potentially serious gram +ve infections, Respiratory tract infections, Septicaemia, Serious infections due to staphylococcus aureus, Skin infections, Soft tissue infections, Urinary tract infection.

    Teicoplanin is contraindicated in conditions like Epilepsy, Convulsions, Hypersensitivity.

    The severe or irreversible adverse effects of Teicoplanin, which give rise to further complications include Bronchospasm, Ototoxicity, Renal failure, Eosinophilia.

    The symptomatic adverse reactions produced by Teicoplanin are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Fever, Tinnitus, Rashes, GI upset, Hearing loss, Angioedema, Rigors, Reaction at injection site.

    Teicoplanin should be used with caution in the patient with hypersentivity to vancomycin, Perform regular hematological, liver, renal and auditory tests. Use with caution during pregnancy and lactation.

    No Information regarding High Risk Group is available.

    Intramuscular, Intravenous
    Community-acquired pneumonia, Complicated skin and soft tissue infections, Complicated urinary tract infections, Hospital-acquired pneumonia

    Adult: In combination with other antibacterial agents: Loading dose: 6 mg/kg 12 hourly for 3 doses. Maintenance: 6 mg/kg once daily, may be adjusted based on the desired target trough concentrations (refer to detailed product guidelines). All doses may be given via IV inj over 3-5 minutes, IV infusion over 30 minutes or via IM inj. Treatment duration must be adjusted according to the type and severity of infection and the patient’s clinical response. Max treatment duration: 4 months.
    Child: ≤2 months Loading dose: 16 mg/kg as a single dose on Day 1. Maintenance: 8 mg/kg once daily starting on Day 2. Doses are given only via IV infusion over 30 minutes; 2 months to 12 years Loading dose: 10 mg/kg 12 hourly for 3 doses. Maintenance: 6-10 mg/kg once daily. Doses are administered via IV inj over 3-5 minutes or IV infusion over 30 minutes; >12 years Same as adult dose.


    Intramuscular, Intravenous
    Bone and joint infections, Infective endocarditis

    Adult: In combination with other antibacterial agents: Loading dose: 12 mg/kg 12 hourly for 3-5 doses via IV inj over 3-5 minutes or IV infusion over 30 minutes. Maintenance: 12 mg/kg once daily via IV inj over 3-5 minutes, IV infusion over 30 minutes or via IM inj; may be adjusted based on the desired target trough concentrations (refer to detailed product guidelines). Treatment duration must be adjusted according to the type and severity of infection and the patient’s clinical response. Minimum treatment duration for infective endocarditis: 21 days. Max treatment duration: 4 months.
    Child: ≤2 months Loading dose: 16 mg/kg as a single dose on Day 1. Maintenance: 8 mg/kg once daily starting on Day 2. Doses are given only via IV infusion over 30 minutes; 2 months to 12 years Loading dose: 10 mg/kg 12 hourly for 3 doses. Maintenance: 6-10 mg/kg once daily. Doses are administered via IV inj over 3-5 minutes or IV infusion over 30 minutes; >12 years Same as adult dose.


    Intravenous
    Continuous ambulatory peritoneal dialysis (CAPD)-associated peritonitis

    Adult: Initially, 6 mg/kg as a single loading dose given via IV. Maintenance (teicoplanin is added to the peritoneal dialysis fluid): 20 mg/L is added in each bag of dialysis solution in the 1st week, followed by 20 mg/L in alternate bags in the 2nd week, and then 20 mg/L in the overnight bag in the 3rd week.


    Oral
    Clostridioides difficile infection

    Adult: As alternative oral treatment (powder for inj/infusion may be used to prepare the oral solution) for antibiotic-associated colitis or diarrhoea caused by Clostridioides difficile: 100-200 mg bid for 7-14 days. Dosage recommendation may vary among individual products or between countries (refer to local detailed product guidelines).

    Teicoplanin

    Inj: 200 mg, 400 mg,